Overview

Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

Status:
Active, not recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine if treatment with bempedoic acid (ETC-1002) versus placebo decreases the risk of cardiovascular events in patients who are statin intolerant.

Phase:

Phase 3

Details

Lead Sponsor:

Esperion Therapeutics
Esperion Therapeutics, Inc.

Collaborator:

The Cleveland Clinic

Treatments:

8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid